Kwaliteitsstandaard atypische parkinsonismen

Pagina 241 97. Lena, Effects of postural exercises in patients with Parkinson's disease and Pisa syndrome : A pilot study. NeuroRehabilitation, 2017. 41 (2): p. 423-428. 98. Capecci, Postural Rehabilitation and Kinesio Taping for Axial Postural Disorders in Parkinson's Disease. Arch Phys Med Rehabil, 2014. 95 (6): p. 1067-75. 99. Warrenburg BPC, C.C., Aisling MR, Phadke R, Holton JL. , The phenomenon of disproportionate antecollis in Parkinson’s disease and multiple system atrophie. Movement disorders, 2007. 22 (16): p. 2325-2331. 100. Wu, C.K. and A.D. Hohler, Management of orthostatic hypotension in patients with Parkinson's disease. Pract Neurol, 2015. 15 (2): p. 100-4. 101. Luciano, G.L., M.J. Brennan, and M.B. Rothberg, Postprandial hypotension. Am J Med, 2010. 123 (3): p. 281 e1-6. 102. Winge, K. and C.J. Fowler, Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord, 2006. 21 (6): p. 737-45. 103. Sakakibara, R., et al., A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn, 2016. 35 (5): p. 551-63. 104. Fasano, A., et al., Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol, 2015. 14 (6): p. 625- 39. 105. Postma, A.G., M. Heesters, and T. van Laar, Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord, 2007. 22 (16): p. 2430-5. 106. Hyson, H.C., A.M. Johnson, and M.S. Jog, Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord, 2002. 17 (6): p. 1318-20. 107. Arbouw, M.E., et al., Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology, 2010. 74 (15): p. 1203-7. 108. Dobkin, R.D., et al., Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol, 2011. 24 (4): p. 206-14. 109. Barone, P., et al., Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 2010. 9 (6): p. 573-80. 110. Rocha, F.L., et al., Antidepressants for depression in Parkinson's disease: systematic review and meta- analysis. J Psychopharmacol, 2013. 27 (5): p. 417-23. 111. Troeung L, E.S., Gasson N. , A meta‐analysis of randomised placebo‐controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS One., 2013(8(11)): p. e79510. 112. Hassink-Franke, L., Terluin, B., Heest van, F.,Hekman, J., Marwijk van, H., Avendonk van M. NHG- standaard Angst . 2012; Available from: https://www.nhg.org/standaarden/samenvatting/angst . 113. Van Weel-Baumgarten EM, V.G.M., Grundmeijer HGLM, Licht-Strunk E, Van Marwijk HWJ, Van Rijswijk HCAM, Tjaden BR, Verduijn M, Wiersma Tj, Burgers JS, Van Avendonk MJP, Van der Weele GM.. NHG- standaard Depressie 2012; Available from : https://www.nhg.org/standaarden/volledig/nhg-standaard- depressie-tweede-herziening . 114. Spijker J, B.C., Meeuwissen JAC, Vliet IM van, Emmelkamp PMG, Hermens MLM, Balkom ALJM and v.n.d.W.M.r.A.D. (2013). Multidisciplinaire richtlijn depressie (3e revisie, 2013) 2013 Available from: https://www.ggzrichtlijnen.nl/depressie . 115. Weintraub, D., Burn, D. J., Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord, 2011. 26 (6): p. 1022-31. 116. Group., T.F.C.P.S., Clozapine in drug‐induced psychosis in Parkinson's disease. Lancet Neurol, 1999. Jun 12 (353(9169)): p. 2041‐2042. 117. Group, T.P.S., Low‐dose clozapine for the treatment of drug‐induced psychosis in Parkinson's disease. N Engl J Med. , 1999. Mar 11 (340(10)): p. 757‐763. 118. Burn, D., et al., Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord, 2006. 21 (11): p. 1899-907. 119. Emre, M., et al., Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med, 2004. 351 (24): p. 2509-18. 120. Poewe, W., et al., Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord, 2006. 21 (4): p. 456-61.